Dr. Ihab discusses case reports and talks about translating CLL-14 and ELEVATE-RR trial data into practice
Dr. Ihab El-Hemaidi, KSA
Dr. Ihab El-Hemaidi, Consultant Adult Haematology/BMT, Joint appointment Assistant Professor of Internal Medicine/Haematology/Oncology, King Saud Bin Abdul Aziz University of Health Sciences, Saudi Arabia, speaks about translating data into practice. Dr
• Two case reports of CLL
• In detail discussion about patient’s diagnosis and initial treatment with ibrutinib and then shift to Venetoclax plus Obinutuzumab based on the CLL-14 clinical trial data
• Second case report of CLL patient with details about the discontinuation of ibrutinib due to severe side effects
• Selection of acalabrutinib based on ELEVATE-RR trial data.
Explore more videos
Review on Time to Progression Regimen in CLL Management
Dr. George Follows, UK
Review on Fixed Duration Regimen in CLL Management
Dr. Mahmoud Marashi, UAE
The CLL Management in Clinic
Dr. Hani Osman, UAE